What To Know: Geron said it intends to sell $175 million of its common stock in an underwritten public offering. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its common stock.

Related Link: Geron Stock Surges After Encouraging Data From Rare Blood Cancer Trial

Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. 

See Also: Why Vyant Bio Shares Are Soaring After Hours

GERN Price Action: Geron shares are down 11.3% in after-hours at $2.83 at the time of publication, according to Benzinga Pro.

Photo: fernando zhiminaicela from Pixabay.